This week, the Rare Disease Company Coalition (RDCC) and the Alliance for Regenerative Medicine (ARM) sent a joint letter to Congressional leadership urging the swift reauthorization of the Rare Pediatric Disease Priority Review Voucher (PRV) program. The letter was signed by over 60 CEOs of biopharmaceutical companies at the helm of rare disease innovation.
To date, this PRV program has catalyzed the development of therapies across 47 rare disease indications and benefited more than 200,000 patients living with a rare disease. Reauthorizing the program through passage of the Give Kids a Chance Act is crucial to ensuring continued progress and hope for the millions of Americans living with rare diseases.
To read our letter, click here.